RELEASE: Suvoda launches eCOA-specific language and design toolkit

(Information sent by the signatory company).

RELEASE: Suvoda launches eCOA-specific language and design toolkit

(Information sent by the signatory company)

- Suvoda releases eCOA-specific language and design toolkit as solution moves into second phase of early adoption program

Practical and innovative functionality seeks to ease eCOA burdens, reduce time-to-launch, and improve the site, physician, and patient experience

PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company specializing in complex studies in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases, announced today that, as As part of its single platform launch, its electronic clinical outcome assessments (eCOA) solution moves into the second phase of the Early Adopter program. Designed to work seamlessly with Suvoda IRT and eConsent, this solution focuses on addressing historical inefficiencies that continue to plague eCOA, such as gaps in overall delivery and execution quality, time-consuming translation and localization processes and logistics related to device management.

"eCOA is not a new concept, however, sponsors and CROs, and more importantly, clinical trial participants have yet to deliver on the full promise of this eClinical technology," explained Jill Platko, vice president of services Suvoda scientists. "In support of Suvoda's mission to improve the clinical trial process, Suvoda didn't want to simply offer another eCOA solution. Instead, they wanted to dive into the gaps that make current eCOA implementations so challenging."

Practical innovations simplify eCOA implementations

As it moves into the next phase of the early adoption program, Suvoda's eCOA solution incorporates input from its customers and includes reimagined processes in four key areas that have proven critical to successful eCOA implementations:

1. Design and creation of questionnaires

Suvoda eCOA introduces a unique, easy-to-use, configuration-based toolkit designed to simplify and speed up eCOA configuration and delivery. Within it, Suvoda offers a proprietary domain-specific language and authoring tool that is tailor-made for eCOA questionnaires.

An innovative addition to the current eCOA product landscape, this tool simplifies the creation of eCOA questionnaires, speeds up localization, and improves access to previews. Questionnaires can also be defined, tuned, translated, validated, and reused across all modalities and devices, all in a regulatory-compliant environment. This licensing and localization functionality includes direct access for translation providers to further streamline workflows and timelines to better meet the needs of any protocol, now and in the future.

2. Logistics of devices

Building on its 10 years of experience in managing the most pressing moments in thousands of trials around the world with its IRT solution and support, Suvoda is uniquely positioned to set the standard for eCOA device logistics. eCOA prioritizes the user experience. With proven clinical trial supply chain and data management processes already in place, Suvoda eCOA will further enhance real-time data capture and simplify device logistics for clinical trial sites, sponsors and patients globally.

3. Real-time customer service/support

With the global capacity of its devices and sites, Suvoda supports mission-critical issues in real time, maintaining its reputation for responsive and reliable customer support. In keeping with its consistently high customer satisfaction scores, the company made it a priority to provide the same level of global support excellence for its eCOA customers.

4. Integrity of patient data through a single platform approach

Suvoda's eCOA, together with its market-leading IRT solution on a single platform built organically together with eConsent, ensures a worry-free and simplified approach by reducing the number of integrations required for a clinical trial. This seamless integration ensures that patient data will be seamlessly collected and shared across the platform, giving users greater accessibility to data that is normalized, compliant, unified, and ready for analysis. This is a significant advancement that improves data integrity, positively impacts trial timelines and results, and creates a more unified user experience for patients and site users.

"With a proven track record of delivering and executing services in thousands of clinical trials around the world, Suvoda specializes in managing the demands of time-sensitive and critical patient interactions," said Suvoda Product Manager, E.K. Koh. "We are logistics leaders in the clinical trial arena, and the addition of eCOA to our platform further ensures that we are centering the digital patient experience without increasing complexity."

Suvoda continues to accept participants in the Early Adopter program as eCOA moves to the next phase. Additional enhancements will be released in early 2023. Click here to learn how to become an early adopter.

About Suvoda

Suvoda is a global clinical trials technology company specializing in complex life support studies in therapeutic areas such as oncology, central nervous system (CNS) and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda enables clinical trial professionals to manage the most pressing moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside of Philadelphia, Suvoda also has offices in Portland, Oregon, Barcelona, ​​Spain, Bucharest, Romania, and Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) close to 70, which is well above the tech industry average of 50, and has been selected by trial sponsors and CROs to support more than 1,000 trials in 65 countries. For more information, visit Follow Suvoda on Twitter and LinkedIn.

Media Contact: Morgan Reese,

Logo -

View original content: